Log inSign up
Pharma-Marketing.comPharma-Marketing.com
  • Industry
  • Digital Health & AI
  • Channels
  • People
  • Agencies
  • Glossary
Log inSign up
  • Terms of Service
  • Privacy Policy
  • Cookie settings
  • Imprint
Pharma-Marketing.com


All rights reserved.

We use AI tools in the creation of certain content.

Pharma Marketing

Data-privacy settings

We use cookies to improve our website and services. They help us understand how visitors use our website. Some cookies are required for the website to function. These are marked as “essential” in the details.

AcceptEssential cookie
NameData-privacy settings
ProviderPharma-Marketing.com
PurposeStores these privacy settings in your browser.
Privacy policyPrivacy policy
Cookiespm_data_privacy
Cookie expiration180 days
Accept
NameGoogle Analytics
ProviderGoogle LLC
PurposeCookies by Google are used for website analytics. Generates statistical data on how the visitor uses the website.
Privacy policyPrivacy policy
Cookies_ga, _gat, _gid
Cookie expiration2 Years
Accept
NameGoogle Ads
ProviderGoogle LLC
PurposeCookies by Google Ads are used for advertising and targeting purpose.
Privacy policyPrivacy policy
Cookies__gsas, __gpi, __gpi_optout, NID, DSID, test_cookie, id, __gads
Cookie expiration2 Years
Accept
NameFacebook
ProviderFacebook Inc.
PurposeCookies by Facebook are used for advertising and marketing activities. Generates statistical data on how the visitor uses the website.
Privacy policyPrivacy policy
Cookies_fbp, fr
Cookie expiration2 Years
Accept
NameMicrosoft Clarity
ProviderMicrosoft Corporation
PurposeCookies by Microsoft Clarity are used for website analytics, heatmaps, and session recordings. They help us understand how visitors interact with our website so we can improve usability and performance.
Privacy policyPrivacy policy
Cookies_clck, _clsk, CLID, ANONCHK, MR, MUID, SM
Cookie expirationUp to 1 Year
© Image: Sanofi

Thursday, August 13, 2026

NAD recommends changes to Sanofi Dupixent advertising

Sanofi has been advised to revise or discontinue selected U.S. advertising claims for Dupixent following a challenge from Galderma Laboratories. The recommendation came from the National Advertising Division, the advertising self-regulatory body run by BBB National Programs.

The disputed messages covered longer-lasting clearer skin and rapid itch relief. The case included consumer-facing claims as well as a prescriber-directed statement.

NAD calls for clearer context in TV claims

The NAD found that Sanofi had evidence to support some aspects of its messaging. According to the review, some adults achieved clearer skin that lasted from four months to one year, and some patients reported itch relief two weeks after the first dose.

However, the NAD recommended that Sanofi adjust its TV advertising so that response rates are disclosed clearly and prominently. It also said the ads should make clear that Dupixent was used together with topical corticosteroids in the relevant treatment setting.

The self-regulatory body also took issue with an animated consumer video explaining the drug’s mechanism of action. In the NAD’s view, the video likely communicated an unsupported message that blocking IL-4 and IL-13 signaling alone is sufficient to address eczema. Dupixent targets IL-4 and IL-13.

Day 2 itch claim falls short

A prescriber-facing claim that Dupixent reduced itch starting as early as Day 2 was also challenged. The NAD concluded that the post hoc analysis behind the statement did not support the message that Dupixent showed a meaningful treatment benefit beginning that early.

Sanofi stated in its advertiser response that it would follow the NAD’s recommendations.

Several Sanofi claims survive the challenge

Galderma did not prevail on all points. The NAD found support for claims that Dupixent helps patients stay ahead of eczema and can help heal skin from within. It also found support for Sanofi’s statement that many adults saw 90 percent clearer skin.

Sanofi may continue using the 90 percent claim, although the NAD advised the company not to overstate the evidence or obscure the treatment context.

The NAD also sided with Sanofi on whether the challenged ads communicated that Dupixent is superior to all other FDA-approved eczema treatments. Galderma’s arguments that the advertising implied Dupixent prevents eczema progression or blocks the most important source of inflammation were not accepted.

Advertising dispute reflects market competition

The decision is part of a broader advertising clash between the two companies. Last year, in two cases brought by Sanofi, the NAD recommended that Galderma change or discontinue certain claims for Nemluvio.

The commercial backdrop is a growing contest in conditions such as prurigo nodularis and eczema. Dupixent remains a major multi-indication product for Sanofi, with second-quarter sales of 5.2 billion euros, or 6 billion U.S. dollars.

Nemluvio, approved by the FDA in 2024, is also gaining traction. Galderma reported first-half 2026 sales of 433 million U.S. dollars, up more than 100 percent. The U.S. accounted for most sales, and eczema contributed more than prurigo nodularis. From mid-June to early July, Galderma said Nemluvio represented 42 percent of new patient starts in prurigo nodularis and 9 percent in eczema in the U.S.

Advertisement

Only a few physicians log in to your website?

Advertisement

A login that sets a new standard for authenticating HCPs and equips your marketing team with everything they need to successfully promote Rx-products. Learn more on DocID.pro


Stay up to date!

Subscribe to our free Pharma-Marketing-Newsletter.


A Partner For Successful Marketing in Pharma & Healthcare

Advertisement

8awake, the specialized agency for pharma and healthcare marketing, supports you with the successful development and execution of winning campaign activities in healthcare.

Leading providers in pharma and healthcare marketing

Sponsored
  • MINTT Digital
  • 8awake
  • MINTT Digital

  • 8awake

    The leading Healthcare & Pharma-Marketing-Agency

Looking for a new partner in pharma and healthcare marketing?

Visit our agency finder

Copyright 2026 Pharma-Marketing.com.